Chwistek Marcin
Department of Hematology and Medical Oncology, Fox Chase Cancer Center/Temple Health, Philadelphia, PA, USA.
F1000Res. 2017 Jun 20;6:945. doi: 10.12688/f1000research.10817.1. eCollection 2017.
Cancer pain remains a significant clinical problem worldwide. Causes of cancer pain are multifactorial and complex and are likely to vary with an array of tumor-related and host-related factors and processes. Pathophysiology is poorly understood; however, new laboratory research points to cross-talk between cancer cells and host's immune and neural systems as an important potential mechanism that may be broadly relevant to many cancer pain syndromes. Opioids remain the most effective pharmaceuticals used in the treatment of cancer pain. However, their role has been evolving due to emerging awareness of risks of chronic opioid therapy. Despite extensive research efforts, no new class of analgesics has been developed. However, many potential therapeutic targets that may lead to the establishment of new pharmaceuticals have been identified in recent years. It is also expected that the role of non-pharmacological modalities of treatment will grow in prominence. Specifically, neuromodulation, a rapidly expanding field, may play a major role in the treatment of neuropathic cancer pain provided that further technological progress permits the development of non-invasive and inexpensive neuromodulation techniques.
癌症疼痛在全球范围内仍然是一个重大的临床问题。癌症疼痛的原因是多因素且复杂的,并且可能因一系列肿瘤相关和宿主相关的因素及过程而有所不同。人们对其病理生理学了解甚少;然而,新的实验室研究表明,癌细胞与宿主的免疫系统和神经系统之间的相互作用是一种重要的潜在机制,可能与许多癌症疼痛综合征广泛相关。阿片类药物仍然是治疗癌症疼痛最有效的药物。然而,由于对慢性阿片类药物治疗风险的认识不断提高,它们的作用一直在演变。尽管进行了广泛的研究,但尚未开发出新型镇痛药。然而,近年来已经确定了许多可能导致新型药物问世的潜在治疗靶点。预计非药物治疗方式的作用也将日益突出。具体而言,神经调节这一迅速发展的领域,若能在技术上取得进一步进展,开发出非侵入性且廉价的神经调节技术,可能在神经性癌症疼痛的治疗中发挥重要作用。